Dr Smitha is an experienced Hematologist in Hennur Road with 10+ years of experience in diagnosing and treating complex blood disorders, paediatric cancers, and bone marrow transplantation.
Trained at reputed tertiary cancer centres, she is widely consulted as one of the Best Hematologists in Bangalore for evidence-based and advanced haematology care.Her clinical focus includes anaemias, clotting disorders, leukemias, lymphomas, bone marrow failure syndromes and paediatric solid tumours.
She works at SPARSH Hospital and is known for her compassionate approach, clear communication and commitment to long-term patient outcomes.
Haematological disorders both benign and malignant conditions, malignant brain tumours, solid malignancies Ewings and osteosarcomas, and bone marrow transplant.
- Received multiple certifications both nationally and internationally.
- Attended training sessions to upgrade my skills to meet current standards.
Problem solving for better health – sponsored by DREYFUS HEALTH FOUNDATION, NEW YORK, USA
- New strategies in bone marrow transplant
- Brain tumors
- Cart cell therapy and advanced clinical research
- Prophylactic Granulocyte transfusions in patients post high dose chemotherapy/ hematopoietic stem cell transplant.
- Stroke in Sickle Cell Disease (SCD): Disease in Text book Elsevier by Dr Smitha and Dr Intezar
- Genomic profiling of Pediatric Hematology and Oncology patients using NGS:Single center experience -PHOCON 2024
- A Retrospective Multicentric INPHOG Study (Inpog-WT-18-02): Patterns of Care and Survival of Wilms Tumors in Children in India
- Revealing GFI-1b mutation as a storm in child previously diagnosed
- with ITP : E poster to ISBMT May 2024
- Hidden DOCK8 mutation in a child with Hyper IgE syndrome: E poster to ISBMT May 2024
- RAS Associated Leukoproliferative Disorder (RALD) due to NRAS
- Mutation Progressing to Acute Myeloid Leukemia: E Poster to 5th Emirates Pediatric Hematology and Oncology conference Jan 2023
- AML with Good risk Cytogenetics t(8;21) having horrendous
- Course due to Associated Systemic Masto cytosis : E Poster to 5th Emirates Pediatric Hematology and Oncology conference Jan 2023
- Elderheim Chester disease in a case of Infantile Leukemia : Case Report
- Disseminated Candidiasis in a case of ALL : Case Report
- Pedicon : Participated in Bangalore Pedicon 2016PET (Pediatric Epilepsy Training) : Conducted by BPNA (British Pediatric Neurological Association)
- IAP: 54th Annual Conference, Basic Mechanical Ventilation in Pediatrics & Poster presentation on Parkes weber syndrome
- Respicon : Participated in Respicon 2017 at 3rd Asian Pediatric pulmonology Society Meeting
- OSCE : Conducted by Texila American University in association with KMC
- Karnataka Pedicon 2017 : Poster presentation of Prider Willi & EBV associated HLH syndrome
- Investigator Meeting : Attended meeting in Dubai for Pain management trial which involves Sativex as the study drug & various other meetings.
- ICH GCP training : Conducted for a Phase III trial from Wyeth Pharmaceutical Ltd and GW pharmaceuticals.
- •Co-Investigator in Recurrent Metastatic Colorectal Phase III trial which involves Photo Dynamic therapy along with regular Chemotherapy.
- Phase I/II Trial for the investigational Targeted drug along with Herceptin in Newly diagnosed Metastatic Breast Cancer- INCYTE Global /Siroclinpharm®
- Phase II trial with investigational agent along with Paclitaxel and carboplatin in LABC/ Metastatic Breast cancer- PEREGRINE Co ®
- Phase III trial in Relapsed and Refractory Non-Hodgkin’s Lymphoma with Rituximab and anti CD 22 MAB compared to investigator choice of Chemo agent – Wyeth®
- Phase III trial in Metastatic RCC with Temsirolimus and Bevacizumab- Wyeth®, experience in e CRF.
- Cancer Pain study
- Capecitabine Bioequivalence Study, MBC and CRC
- CDX-110-04 An international randomized double blind controlled study of GM-CSF with adjuvant temozolomide in patients with newly diagnosed surgically resected EGFRV3 positive Glioblastoma Act-IV study
- A Randomized open label phase II study to assess the efficacy & safety of AZD4547 monotherapy VS Paclitaxel in patients with advanced Gastric adenocarcinoma (including lower 1/3rd of esophagus/GE Junction) with FGFR2 Polysomy or Gene amplication (Shine Study)
Indian Pediatric Hematology Oncology Group (PHO- IAP)
